Senegal’s DREPAF Breakthrough and Africa’s First Locally Manufactured Sickle Cell Treatment
Senegal’s DREPAF Breakthrough and Africa’s First
Locally Manufactured Sickle Cell Treatment
.png)
Executive Summary
Senegal has achieved a significant milestone in African pharmaceutical manufacturing by producing DREPAF, a locally manufactured generic hydroxyurea medicine used to treat sickle cell disease (SCD). The drug is produced by the Senegalese pharmaceutical company Teranga Pharma and is widely reported as the first African-manufactured clinical treatment for sickle cell disease based on hydroxyurea, the World Health Organization's recommended disease-modifying therapy for SCD. turn1search3
The development is particularly important because Africa carries the largest burden of ickle cell disease globally, with nearly 80% of cases occurring on the continent, while access to treatment has historically depended on imported medicines that are often expensive and difficult to obtain. turn1search6
1. Understanding Sickle Cell Disease
Sickle cell disease is a hereditary blood isorder that causes red blood cells to become rigid and crescent-shaped rather than round and flexible. These abnormal cells can block blood vessels, leading to:
- Severe pain crises
- Chronic anemia
- Stroke
- Organ damage
- Increased risk of infection
- Reduced life expectancy
According to sources cited in reporting on DREPAF, approximately two-thirds of global cases occur in sub-Saharan Africa, and hundreds of thousands of infants are born annually with the disease throughout the region. turn1search1
2. What is DREPAF?
DREPAF is a generic hydroxyurea-based medicine developedand manufactured in Senegal by Teranga Pharma. Hydroxyurea is considered the international gold-standard medicine for managing sickle cell disease. turn1search3
How Hydroxyurea Works
Hydroxyurea stimulates the body to produce more fetal hemoglbin (HbF), which helps prevent red blood cells from acquiring the sickle shape. This action:
- Reduces vaso-occlusive crises
- Lowers hospitalization rates
- Decreases blood transfusion requirements
- Improves overall quality of life
These benefits have been recognized by the World Health Organization and medical research institutions. turn1search3
3. The Company Behind the Innovation
DREPAF is manufactured by *Teranga Pharma, a Senegalese pharmaceutical company based near Dakar.
The company's CEO, Mouhamadou Sow, stated that one of the primary objectives was to expand access to hydroxyurea for African patients who previously depended on imported medicines. He noted that many doctors were forced to treat the consequences of sickle cell disease rather than addressing its biological causes because of limited access to hydroxyurea. turn1search3
4. Why This Development Matters
4.1 Pharmaceutical Sovereignty
The productin of DREPAF represents a step toward what many African policymakers call pharmaceutical sovereignty.
Historically:
- Most advanced medicines used in Africa are imported.
- International supply-chain disruptions often affect availability.
- Imported drugs can be prohibitively expensive.
Local manufacturing reduces dependence on external suppliers and strengthens Africa's health security. turn1search8
4.2 Better Access
Several reports indicate that DREPAF is substantially cheaper tha imported hydroxyurea products. Imported alternatives such as Hydrea and Siklos can cost up to three times more. turn1search7
Improved affordability may allow:
- Earlier treatment initiation
- More regular medicaion use
- Reduced healthcare costs
- Improved patient outcomes
turn1search7
5. Pediatric Innovation
One important feature of DREPAF is the availability of pediatric formulation.
The product is available in:
- 500 mg doses for adults
- 100 mg doses for children
Reports indicate the pediatric version can be used in children from nine months of age, addressing a major treatment gap in Africa where childhood mortality from sickle cell disease remains high. turn1search6
6. Economic and Industrial Impact
The project received approximately 4 billio CFA francs (about US$7.1 million) in funding. turn1search6
Potential impacts include:
Job Creation
- Growth of Senegal's pharmaceutical indusry.
- Expansion of research and manufacturing capacity.
Technology Transfer
- Development of local expertise in drug manufacturing.
- Strengthening of African pharmaceutical supply chains.
Regional Exports
Several African countries have reportedly expressed interest in obtaining DREPAF, creating opportunities for regional trade and health cooperation. turn1search5
7. Public Health Significance
Africa accounts for approximately 80% of global sckle cell disease cases. turn1search6
Persistent challenges include:
- Lack of early diagnosis
- Limited access to medicatios
- Shortages of hydroxyurea
- High treatment costs
A 2023 study cited in reporting found that many healthcare professionals in French-speaking sub-Saharan Africa reported frequent disruptions in hydroxyurea supplies. turn1search7
The emergence of a reliable African production source may help address these problems.
8. Challenges Ahead
Despite the breakthrough, several challenges remain.
Scaling Production
Demand across Africa is enormous, and production capacity must increase significantly.
Regulatory Approvals
Each African country requires regulatory authorization before importation and distribution.
Distribution Infrastructure
Remote and rural communities may still face difficulties accessing treatment.
Healthcare Training
Doctors and healthcare workers require adequate training on hydroxyurea use and monitoring.
9. Strategic Significance for Africa
The DREPAF initiative fits into broader continental efforts to:
- Expand local pharmaceutical manufacturing.
- Reduce dependency on imported medicines.
- Improve access to essential treatments.
- Advance health security and self-reliance.
The project demonstrates that African pharmaceutical companies can move beyond packaging and distribution into the full development and manufacture of critical medicines. turn1search8
Conclusion
Senegal's production of DREPAF represents one of the most significan recent pharmaceutical achievements in Africa. By manufacturing a hydroxyurea-based treatment locally, Senegal has improved the prospects for affordable and sustainable sickle cell disease care across the continent. While DREPAF is not a cure, it is an established therapy that can substantially reduce suffering, hospitalizations, and disease complications. Its local production may serve as a model for future African-led pharmaceutical innovation and regional health security. turn1search3
Full Resources and References
Primary News Sources
- Africanews. Senegalese copany produces first Africa-made treatment for sickle cell disease. August 2026. [africanews.com]
- Medical Xpress / AFP. Senegal-made sickle cell treatment raises hopes, reduces costs. August 2026. [medicalxpress.com]
- Yahoo News. Pharmaceutical Company In Senegal Produces First African-Made Clinical Treatment For Sickle Cell. September 2026. [yahoo.com]
Additional Reporting
- Pulse Ghana. Senegal Produces First Africa-Made Generic Sickle Cell Drug. [pulse.com.gh]
- Africa Global News. Senegal Produces Africa's First Locally Made Sickle Cell Drug. [africaglobalnews.com]
- UrbanGeekz. Senegalese Company Launches Africa's First Homegrown Sickle Cell Medicine. [urbangeekz.com]
Scientific and Institutional Sources Mentioned in Reporting
World Health Organization (WHO) guidance on sickle cell disease and hydroxyurea therapy. Mentioned in reporting. [medicalxpress.com], [africanews.com]
National Institutes of Health (NIH) information on hydroxyurea and fetal hemoglobin production. Mentioned in reporting. [yahoo.com]
American Society of Hematology publications concerning sickle cell disease prevalence and treatment access. Mentioned in reporting. [yahoo.com], [dailynews.co.za]
Blood Journal (American Society of Hematology), 2023 study regarding hydroxyurea supply disruptions in Francophone Sub-Saharan Africa. Referenced in news coverage. [dailynews.co.za]
.jpg)
.jpg)
.jpg)
تعليقات
إرسال تعليق